Our technology platform for translational cancer research, anti-cancer drug discovery, and drug development, uses a polymer-based electro-spun fiber-inspired smart scaffold (FiSS) technology that promotes aggregation of tumor cells resulting in tumor-like organoids (tumoroids)



Advantages of this Platform

  • Tumoroids grow as a “bead on a rope” culturable up to 20 days or longer becoming >500 µm in size
  • Easy dislodgement of tumoroids without any need for trypsinization for further downstream analysis
  • These tumoroids undergo an Epithelial Mesenchymal Transition (EMT) in 3 days; a process by which epithelial cells lose their cell polarity and cell-cell adhesion and gain migratory and invasive properties to become mesenchymal stem cells
  • Drug response profile of tumoroids is similar to in vivo tumors, thereby providing the opportunity of developing a individualized Prescription Enhancement (iPEN)  test platform that enables selecting right cancer therapy for an individual patient

Assay for CSC drug discovery uses a platform technology, which has several advantages:

  • Tumoroids develop from tumor cell lines or co-cultures of tumor, fibroblast and endothelial cells
  • Faster (2X) growth rate of tumoroids vs other 3D systems
  • Culture wells are suitable for direct screening without transfer and compatible with standard assays: CellTiterGlo, PrestoBlue, WST
  • Available in both 96- and 384-well formats
  • Validated in diverse tumor models, including lung, breast, prostate and ovarian cancers and sarcomas
  • Tumoroids/CSCs express relevant clinical markers
  • Adaptable to support patient biopsy cells. TGN’s CSC-based personalized cancer treatment platform will involve culturing tumor biopsy cells from a patient on our FiSS-CSC discs to determine the most effective and safe anti-cancer drug(s) for that patient